Q3 2024 Heartbeam Inc Earnings Call Transcript
Key Points
- HeartBeam Inc (BEAT) has developed a groundbreaking cable-free 12-lead ECG technology that can be used by patients anywhere, offering high-resolution data capture.
- The company is targeting large addressable markets worth over $100 billion annually in the US alone, with a strategy to disrupt traditional cardiac care.
- HeartBeam Inc (BEAT) has a strong pipeline of clinical evidence, with nine peer-reviewed publications and studies involving over 500 patients.
- The company has received industry recognition, including being named a 'Rising Star' at the Digital Health Hub Foundation Awards and winning a MedTech breakthrough award.
- HeartBeam Inc (BEAT) has a robust patent portfolio with 17 issued patents worldwide, supporting its innovative technology.
- The company is still awaiting foundational FDA clearance, which is crucial for its technology and future product submissions.
- HeartBeam Inc (BEAT) reported a net loss of nearly $5 million for the third quarter of 2024, highlighting ongoing financial challenges.
- The cash balance as of September 30, 2024, was $5.8 million, indicating limited financial runway without additional funding.
- The company does not anticipate significant revenue in 2025, suggesting a longer timeline to profitability.
- HeartBeam Inc (BEAT) faces uncertainties related to FDA submission timelines and outcomes, which could impact commercialization plans.
Greetings and welcome to the Heart Beam third quarter, 2024 financial results conference call. At this time, all participants are in a listen-only mode, a question and answer session will follow the formal presentation as a reminder, this conference call is being recorded before we begin the formal presentation. I would like to remind everyone that statements made on the call and webcast may include predictions, estimates or other information that might be considered forward-looking.
While these forward-looking statements represent our current judgment on what the future holds. They are subject to risks and uncertainties that could cause actual results to differ materially. Your caution not to place undue reliance on these forward-looking statements which reflect our opinions only as of the date of this presentation.
Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events.
Throughout today's discussion, we will attempt to present some
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
